Xydalba dalbavancin regulatory update

The European Commission approved an MAA from Actavis for Xydalba dalbavancin to treat acute bacterial skin and skin structure infections (ABSSSIs) in adults. Gruppo Angelini (Rome, Italy) has exclusive rights to commercialize the once-weekly IV antibiotic in 36 countries, including Italy, Spain, Poland, Portugal, Turkey and the Commonwealth of Independent States (CIS) (see BioCentury, Sept. 1, 2014). ...